Dark Matter Blog
APRIL 4, 2023
Prior to 2015, I had a casual relationship, at best, with targeting RNA. Targeting RNA is a Whole New World Then in 2015, I became smitten and eloped with RNA, setting out to build a company devoted to bringing to bear industrial drug discovery concepts and methods on a new problem of drugging RNA with small molecules.
Broad Institute
OCTOBER 28, 2024
We wanted to build a tool like that for cell biology. So we took lots of reference single-cell RNA sequencing data from atlases and used our scalable machine learning algorithms to embed all of the gene expression data on these cells into compact vector representations — you can think of these as a signature for each cell.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
APRIL 9, 2024
In a previous study, we showed that these peptides decorate all cellular RNAs and thus impair the binding of RNA-binding proteins to RNA. Initial works from the lab concentrated on exploring the role of replicative stress in cancer and ageing, for which the group combined cell biology, mouse models and drug development projects.
Drug Target Review
JULY 23, 2024
Shortly after finishing my studies, I landed my first job in industry working on cell biology research for several disease indications. I carried that appetite for knowledge, coupled with a driven work ethic, through my graduate and post-graduate studies at the University College London.
Drug Target Review
AUGUST 24, 2023
Her discoveries on the first-in-class RNA-based innate immune receptor agonist RGT100, built the foundation for the initiation of a Phase I clinical trial as well as the successful acquisition of Rigontec by MSD (known as Merck & Co. Shear forces induce ICAM-1 nanoclustering on endothelial cells that impact on T-cell migration.
Drug Target Review
AUGUST 10, 2023
A twist of fate: GRP78 regulates cell migration and invasion Continuing their exploration of GRP78’s functions in the cell nucleus, the researchers utilised sophisticated RNA sequencing to compare lung cancer cells engineered to over-express nuclear GRP78 with cells lacking it.
Elrig
APRIL 29, 2024
She has played a key role inbuilding the target identification platform and a proprietary database of transcriptome-wide, functional RNA structures. Harini joined Serna Bio in early 2021 and has been an integral part of the multidisciplinary teamworking on target ID platform development to drug discovery.
Expert insights. Personalized for you.
52 
Let's personalize your content